 |
|
|
| |
IDX184, A Liver-Targeted Nucleotide HCV Polymerase Inhibitor:
Results of a First-in-Man Safety and Pharmacokinetic Study
|
| |
| |
44th EASL April 23-26 2009 Copenhagen
Reported by Jules Levin
X.J. Zhou, K. Pietropaolo, J. Sullivan-Bolyai, B. Kuca, W. Liu, L. Xu, B. Belanger, S. Khan and D. Mayers
Idenix Pharmaceuticals, Inc., Cambridge, MA, USA
|
| |
|
|
|
|
|
